Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Jan 4;131(1):e143928.
doi: 10.1172/JCI143928.

Prolonged adaptive immune activation in COVID-19: implications for maintenance of long-term immunity?

Affiliations
Observational Study

Prolonged adaptive immune activation in COVID-19: implications for maintenance of long-term immunity?

Philip A Mudd et al. J Clin Invest. .

Abstract

Ongoing observational clinical research has prioritized understanding the human immune response to SARS-CoV-2 during the coronavirus disease 2019 (COVID-19) pandemic. Several recent studies suggest that immune dysregulation with early and prolonged adaptive immune system activation can result in cellular exhaustion. In this issue of the JCI, Files et al. compared cellular immune phenotypes during the first two months of COVID-19 in hospitalized and less severe, non-hospitalized patients. The authors utilized flow cytometry to analyze circulating peripheral blood mononuclear cells. Both patient cohorts maintained B and T cell phenotypes consistent with activation and cellular exhaustion throughout the first two months of infection. Additionally, follow-up samples from the non-hospitalized patient cohort showed that activation markers and cellular exhaustion increased over time. These findings illustrate the persistent nature of the adaptive immune system changes that have been noted in COVID-19 and suggest longer term effects that may shape the maintenance of immunity to SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: PAM is listed as inventor or coinventor on the following applied for, provisional, or full patents: 019387, “Kits and methods for selecting treatments for respiratory infections”; 019488, “Targeted modulation of the inflammatory cascade in patients with severe viral respiratory illness”; and 019454, “Human COVID mAbs for diagnostics.” PAM’s spouse is employed by AbbVie and receives equity in the company through stock options associated with that employment. KER has provisional patents pending: WUSTL 019522/US, 019522/US2, and 019522/US3 titled “ELISpot Assay to Immune Phenotype Patients.”

Figures

Figure 1
Figure 1. Response to human viral respiratory infections.
(A) In a typical influenza infection, symptoms and viral replication peak within a few days and resolve after the first week; serologic response peaks within the first two weeks and remains high. Notably, with influenza, the cellular immune activation peaks at week one and resolves by week three. (B) In contrast, with SARS-CoV-2 infection, the cellular immune system remains activated despite viral clearance. The persistence of viral antigens, development of T cell exhaustion, and increased risk of secondary infections set SARS-CoV-2 infection apart from other viral respiratory infections.

Comment on

  • Sustained cellular immune dysregulation in individuals recovering from SARS-CoV-2 infection

Similar articles

Cited by

References

    1. Ng S, et al. Novel correlates of protection against pandemic H1N1 influenza A virus infection. Nat Med. 2019;25(6):962–967. doi: 10.1038/s41591-019-0463-x. - DOI - PMC - PubMed
    1. Openshaw PJM, Chiu C, Culley FJ, Johansson C. Protective and harmful immunity to RSV infection. Annu Rev Immunol. 2017;35:501–532. doi: 10.1146/annurev-immunol-051116-052206. - DOI - PubMed
    1. McElroy AK, et al. Human Ebola virus infection results in substantial immune activation. Proc Natl Acad Sci U S A. 2015;112(15):4719–4724. doi: 10.1073/pnas.1502619112. - DOI - PMC - PubMed
    1. Huang C, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi: 10.1016/S0140-6736(20)30183-5. - DOI - PMC - PubMed
    1. Files JK, et al. Sustained cellular immune dysregulation in individuals recovering from SARS-CoV-2 infection. J Clin Invest. 2021;131(1):e140491. - PMC - PubMed

Publication types